- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
29
29 companies
Axsome Therapeutics
Market Cap: US$6.7b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$134.99
7D
4.2%
1Y
51.9%
Zevra Therapeutics
Market Cap: US$571.5m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.18
7D
-8.1%
1Y
19.1%
Caris Life Sciences
Market Cap: US$8.5b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$30.08
7D
-3.2%
1Y
n/a
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.06
7D
20.2%
1Y
-0.5%
Legend Biotech
Market Cap: US$6.0b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$32.40
7D
0.9%
1Y
-25.7%
Soleno Therapeutics
Market Cap: US$3.6b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$67.16
7D
4.6%
1Y
20.2%
ARS Pharmaceuticals
Market Cap: US$885.5m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$8.96
7D
-1.6%
1Y
-41.3%
Vanda Pharmaceuticals
Market Cap: US$257.1m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.35
7D
-20.9%
1Y
-6.7%
Evoke Pharma
Market Cap: US$10.7m
Operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
EVOK
US$5.15
7D
8.4%
1Y
-11.2%
Madrigal Pharmaceuticals
Market Cap: US$9.3b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$418.90
7D
-3.9%
1Y
26.4%
Exelixis
Market Cap: US$10.4b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$38.67
7D
-3.3%
1Y
12.8%
Grace Therapeutics
Market Cap: US$43.6m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$3.16
7D
0.4%
1Y
1.8%
Eton Pharmaceuticals
Market Cap: US$483.0m
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$18.01
7D
-2.4%
1Y
108.9%
AC Immune
Market Cap: US$334.4m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.38
7D
4.0%
1Y
12.7%
Syndax Pharmaceuticals
Market Cap: US$1.2b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$13.70
7D
4.5%
1Y
-27.7%
Kiniksa Pharmaceuticals International
Market Cap: US$2.8b
A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
KNSA
US$37.01
7D
-8.8%
1Y
72.3%
Insmed
Market Cap: US$40.4b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$189.60
7D
18.8%
1Y
177.5%
SIGA Technologies
Market Cap: US$592.9m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$8.28
7D
-1.8%
1Y
18.3%
Krystal Biotech
Market Cap: US$5.7b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$197.51
7D
4.0%
1Y
15.6%
BeOne Medicines
Market Cap: US$34.2b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$310.48
7D
-1.6%
1Y
49.8%
Iovance Biotherapeutics
Market Cap: US$712.9m
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
IOVA
US$1.97
7D
-12.4%
1Y
-82.4%
Day One Biopharmaceuticals
Market Cap: US$762.1m
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$7.44
7D
-0.7%
1Y
-49.2%
Gyre Therapeutics
Market Cap: US$703.9m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$7.75
7D
-5.1%
1Y
-46.4%
Tarsus Pharmaceuticals
Market Cap: US$2.9b
A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
TARS
US$68.81
7D
4.2%
1Y
45.5%
Earth Science Tech
Market Cap: US$69.4m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.24
7D
48.1%
1Y
63.4%
Journey Medical
Market Cap: US$213.6m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$8.12
7D
1.2%
1Y
52.6%
Zai Lab
Market Cap: US$2.9b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$26.13
7D
-0.7%
1Y
-14.2%
Geron
Market Cap: US$803.9m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.26
7D
1.6%
1Y
-69.3%
Avadel Pharmaceuticals
Market Cap: US$1.8b
Operates as a biopharmaceutical company in the United States.
AVDL
US$18.89
7D
1.8%
1Y
27.1%